biomaterials-congress-2019-keynote

6 / 7

Biomaterials Congress 2019 Materials Science and Nanotechnology | Volume 3
Page 25
June 19-20, 2019 | Dublin, Ireland
BIOMATERIALS,
CELLULAR AND TISSUE ENGINEERING
3rd International Conference on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
ENHANCED DNA CONSTRUCTS FOR THE EARLY
DIAGNOSIS OF ALZHEIMER’S IN BLOOD OR DIA-
BETES IN SALIVA USING PHOTONICITY
Unpredictability is the major limitation to the diagnosis and/or cure of
degenerative diseases such as Alzheimer’s and diabetes. In most of the
cases these diseases are only detected after the onset of the disease has
occurred. The combination of very sensitive methods with high expression
of inherent molecules will offset these limitations. Molecules such as DNA,
proteins, and other compounds can be ideal markers for detecting diseases
such as Alzheimer’s and diabetes by non-invasive techniques because of the
inherent biophotonic characteristics. Therefore, researchers have developed
two different DNA sensors using synthetic biology to detect Alzheimer’s
and diabetes prior to the onset of these diseases. The DNA sensor was con-
structed in bacteria or yeast using natural and/or synthetic sequences. The
efficacy of the DNA sensor was tested based on fluorescence intensity when
mixed with human blood plasma using a fluorescence detector at different
wavelengths. The level of fluorescence intensity determines the degree of
the disease; thus, they were able to enhance the photon expression of the
detection by conjugation using a natural dye at a wavelength similar to the
amyloid protein. The intensity of the fluorescence was correlated to clinical
parameters, tomographic images and glycaemia results from patient blood
samples. The expression of amyloid protein was confirmed using standard
techniques including biochemical assays such as ELISA andWestern Blot. The
results of these correlations allowed us to establish three different groups of
patients. In the case of Alzheimer’s, patients were divided into the following
groups: Alzheimer’s diagnosed, pre-Alzheimer’s and normal groups. For dia-
betes, patients were divided into the following groups: diabetic, pre-diabetic
and normal groups. Results were analyzed through statistical methods as
well as using neuronal network computational modeling. This investigation
provides a much needed non-invasive diagnostic approach for developing
proper therapy and treatment for these diseases.
R Cuero, Mater Sci Nanotechnol 2019, Volume 3
R Cuero did his PhD in Microbiology from Uni-
versity of Strathclyde, UK and MSc in Plant Pa-
thology from Ohio State University, USA and BSc
from Heidelberg University, USA and Biology
Degree from Universidad del Valle, Colombia. He
is a former Distinguished Professor and Research
Scientist of Texas A&M University system on the
Campus of Prairie View, Texas. Currently, he is
Chief Scientific Advisor of BioCapital Holdings
LLC., USA and he is Founder/Scientist/Mentor of
the International Park of Creativity, which main
aim is invention/discovery. He is former Research
Associate for USDA. He has many scientific in-
ventions, patents and publications in different
scientific and technological fields including bio-
technology, microbiology, molecular biology,
synthetic and integrated biology, environmental
and energy biotechnology, microbiology and
astrobiology. His most recent inventions are pro-
duction of light without electrical cord or battery
and also development of DNA sensor for early
detection of Alzheimer’s in blood as well as DNA
sensor for early detection of diabetes in saliva.
He has received numerous scientific recognitions
such as the Hispanic Scientist of the year 2013,
USA and he has received several honorary doctor
degrees. He has received the NASA Brief Technol-
ogy award for his inventions to NASA.
R Cuero1,2
1BioCapital Holdings, USA
2International Park of Creativity, USA
BIOGRAPHY